Arcellx is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases.
Location: United States, Maryland, Gaithersburg
Total raised: $324M
Investors 6
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| - | Takeda Ven... | takeda.com |
| - | LG Technol... | lgtechvent... |
| - | JVC Invest... | jvcmanagem... |
| 01.03.2023 | Solasta Ve... | solasta-ve... |
| - | SR One | srone.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 08.02.2022 | - | $124M | - |
| 15.04.2021 | Series C | $115M | - |
| 04.10.2019 | Series B | $85M | - |
Mentions in press and media 12
| Date | Title | Description | Source |
| 08.02.2022 | Arcellx raises $124M in Wall Street debut to bankroll study ... | - | solasta-ve... |
| 15.04.2021 | Arcellx Raises $115M in Series C Financing | Arcellx, a Gaithersburg, Md.-based clinical-stage biopharmaceutical company advancing a pipeline of ... | finsmes.co... |
| 14.04.2021 | Money Moves: Eye-catching VC rounds from HawkEye 360, Territ... | Money Moves is a column where we chart the funding raises of tech companies across the region. Have ... | technical.... |
| 13.04.2021 | Arcellx Closes $115 Million Series C Financing to Advance it... | GAITHERSBURG, Md., April 13, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage bioph... | marketscre... |
| 13.04.2021 | Arcellx Closes $115 Million Series C Financing | GAITHERSBURG, Md., April 13, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage bioph... | citybizlis... |
| 04.10.2019 | Arcellx Lands $85M Series B Round to Fend Off Cancer Cells | Another young biotech firm is raking in the capital. Gaithersburg, Md.-based Arcellx has closed on ... | bizjournal... |
| 04.10.2019 | Arcellx Raises $85 Million in a Series B Financing | GAITHERSBURG, Md., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Arcellx, a privately-held biopharmaceutical com... | citybizlis... |
| 04.10.2019 | Arcellx raises $85M to take anti-BCMA cell therapy into huma... | Arcellx has raised $85 million to advance cell therapies designed to be safer and more effective tha... | fiercebiot... |
| 04.10.2019 | Arcellx Raises $85 Million in a Series B Financing to Advanc... | GAITHERSBURG, Md., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Arcellx, a privately-held biopharmaceutical com... | citybizlis... |
| 03.10.2019 | Arcellx Raises $85 Million in a Series B Financing to Advanc... | - | solasta-ve... |
Show more